Dr. Vladimir Vainstein

Vladimir is a Medical Doctor at the Hadassah Medical Center in Jerusalem. He holds a B.Sc. degree in Medical Sciences from the Hebrew University, M.D. degree from the Hebrew University & Hadassah Medical School, and an M.Sc. degree from the Department of Experimental Medicine and Cancer Research in the faculty of Medicine at the Hebrew University of Jerusalem. His M.Sc. research, carried out under the supervision of Prof. S.A. Ben-Sasson, involved the use of pathway inhibitors for the C-terminal post-translational modification of proteins, as a possible avenue for developing anti-angiogenesis therapy. Dr Vainstein successfully finished residency in Internal medicine Department at Hadassah Medical Center Campus Mt Scopus, Jerusalem, and fellowship in Hematology Department at Hadassah Medical Center, Ein Kerem, Jerusalem. In IMBM he took part in several projects including modeling human ganulopoiesis and chemotherapy-induced myelotoxicity, optimization of the immunotherapy of acute myeloid leukemia, and cancer stem cell modeling. is a Medical Doctor at the Hadassah Medical Center in Jerusalem. He holds a B.Sc. degree in Medical Sciences from the Hebrew University, M.D. degree from the Hebrew University & Hadassah Medical School, and an M.Sc. degree from the Department of Experimental Medicine and Cancer Research in the faculty of Medicine at the Hebrew University of Jerusalem. His M.Sc. research, carried out under the supervision of Prof. S.A. Ben-Sasson, involved the use of pathway inhibitors for the C-terminal post-translational modification of proteins, as a possible avenue for developing anti-angiogenesis therapy. Dr Vainstein successfully finished residency in Internal medicine Department at Hadassah Medical Center Campus Mt Scopus, Jerusalem, and fellowship in Hematology Department at Hadassah Medical Center, Ein Kerem, Jerusalem. In IMBM he took part in several projects including modeling human ganulopoiesis and chemotherapy-induced myelotoxicity, optimization of the immunotherapy of acute myeloid leukemia, and cancer stem cell modeling.

Scientific activity in 2010

Over the past year, Vladimir has been involved in th mathematical modeling of leukemic transformation in myelodysplastic syndrome patients. The goal is to study the genetic mechanisms underlying this transformation, in order to assist hematologists in evaluating the transformation risk and in planning the treatment. The project is carried out in collaboration with the Department of Hematology at Heinrich Heine University, Dusseldorf.

Vladimir currently holds a Post Doctoral position as a researcher at the Center for Molecular Pathways and Drug Discovery, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.

Publications

  1. Jager E., van der Velden V.H.J, te Marvelde J.G. Agur Z, Vainstein V. Physiologically-based mathematical model of targeted drug delivery: implications for choice of treatable patient population and treatment strategy. In preparation.
  2. Kirnasovsky O., Kogan Y., Vainstein V. & Agur Z, Investigation of tumour dynamics by mathematical modelling at the cellular level. In preparation.
  3. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother. 2008 57(3):425-39.
  4. Agur Z., Elishmereni M., Kogan Y., Kheifetz Y., Ziv I., Shoham M. Vainstein V. Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study. In Preclinical development handbook. Ed. Gad, S. 2008 1229–1266. New York: John Wiley and Sons.
  5. Kogan Y., Ribba B., Dahan N., Marron K., Vainstein V., Agur Z. Intensifed Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement. Mathematical Modelling of Natural Phenomena 2007 2(3), pp. 47-68.
  6. Kronik N., Kogan Y., Vainstein V., Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas by a computerized model. Cancer Immunol Immunother..2007 57, 425–439.
  7. Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., Agur Z. Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor: Insights from a Computerized Model of Human Granulopoiesis. MMMP. 2006 1(2), 70-80.
  8. Vainstein V., Ginosar Y., Shoham M., Yanovsky A., Ranmar D., Agur,Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol. 2005 234, 311–327.
  9. Arakelyan L., Merbl Y., Daugulis P., Ginosar Y., Vainstein V., Kogan Y., Sleitser V., Harpak H., Agur Z. Using multi-scale mathematical modeling in anti-angiogenic therapy. In Cancer modeling and simulation: Mathematical biology and medicine series. Chapman & Hall/CRC. 2003 185-221.
  10. Arakelyan L., Merbl Y., Daugilis P., Ginosar Y., Vainstein V., Selitser V., Kogan Y., Harpak H., Agur Z. Multi-Scale Analysis of Angiogenic Dynamics and Therapy (2003) In Cancer Modelling and Simulation (ed. L. Preziosi) CRC Mathematical Biology and Medicine Series CRC Press UK.
  11. Arakelyan L., Vainstein V., & Agur Z. A computer algorithm describing angiogenesis and vessel maturation and its use for studying the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 2002 5, 203–214.

Publications

  1. Arakelyan L., Merbl Y., Vainstein V., Agur Z. A new cancer drug regimen based on the interplay between tumor growth and angiogenesis – Predictions of a mathematical model. SIAM Conference on the Life Sciences. Raleigh, North Carolina, 31July – 4 August 2006.
  2. Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., Ariad S., Chan S., Agur Z. Clinical validation of a physiologically-based computer model of human granulopoiesis and its use for improving cancer therapy by Doxorubicin and Granulocyte colony-stimulating factor (G-CSF). 48th Annual Meeting of the American Society of Hematology, Orlando, Florida, 9-12 December 2006.
  3. Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z. Using In Silico thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, EHO (2003).
  4. Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z, Using Virtual thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham . Hematology Journal. 2003;4(suppl 2):224.
  5. Arakelyan L, Vainstain V, and Agur Z. Optimizing anti-angiogenic therapy using mathematical tools. Proceedings of American Society of Clinical Oncology (ASCO), 2002.21, p. 440a.

    About IMBM | Scientific Board | IMBM Members | Research Projects | Applications
    Join Us | Press Release | Events | Publications | HOME